1. Home
  2. CRSP

CRSP

CRISPR Therapeutics AG

Logo CRISPR Therapeutics AG

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

as 04-18-2024 3:58pm EST

$
-
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Crispr Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.

Founded: N/A Country:
Switzerland
Switzerland
Employees: N/A City: ZUG
Market Cap: 4.9B IPO Year: 2016
Target Price: $81.44 AVG Volume (30 days): 1.8M
Analyst Decision: Buy Number of Analysts: 18
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -1.94 EPS Growth: N/A
52 Week Low/High: $37.55 - $91.10 Next Earning Date: 05-06-2024
Revenue: $371,206,000 Revenue Growth: 30885.48%
Revenue Growth (this year): -70.01% Revenue Growth (next year): 275.17%

Share on Social Networks: